GlassScriptPhysician profile
April O Swoner
NPI 1972007201
$246,466.42
in general payments reported to CMS, 2019-2025
67 companies · $81K in 2025
The $81K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $67K · 2022: $45K · 2023: $16K · 2024: $37K · 2025: $81K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $63K · Honoraria: $29K · Food and Beverage: $29K · Travel and Lodging: $12K · Consulting Fee: $1,100 · Education: $21.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62,787.28 |
| Honoraria | $29,332.25 |
| Food and Beverage | $28,645.21 |
| Travel and Lodging | $11,830.31 |
| Consulting Fee | $1,100.00 |
| Education | $21.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $49,352.74 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $38,191.87 | 2021-2025 | Nuplazid, Daybue |
| Biohaven Pharmaceuticals, INC. | $33,090.12 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25,963.02 | 2022 | |
| Ani Pharmaceuticals, INC. | $25,297.41 | 2022-2025 | Purified Cortrophin Gel |
| Amgen INC. | $15,803.47 | 2021-2025 | Uplizna, Aimovig |
| Axsome Therapeutics, INC. | $11,967.51 | 2025 | Symbravo |
| Pfizer INC. | $9,546.17 | 2023-2025 | |
| Mdd US Operations, LLC | $6,456.76 | 2021-2025 | Gocovri, Apokyn, Myobloc |
| Ucb, INC. | $3,278.00 | 2021-2025 | Briviact, Rystiggo, Fintepla |
| Emd Serono, INC. | $2,563.07 | 2021-2025 | Mavenclad |
| Allergan, INC. | $2,265.82 | 2021-2022 | |
| Biogen, INC. | $2,152.24 | 2021-2025 | Vumerity, Tysabri, Avonex |
| Neurocrine Biosciences, INC. | $1,941.27 | 2021-2025 | Ingrezza, Ongentys |
| Sk Life Science, INC. | $1,639.41 | 2021-2025 | Xcopri |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,624.44 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,409.63 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Alexion Pharmaceuticals, INC. | $1,236.85 | 2021-2025 | Ultomiris, Soliris |
| Tg Therapeutics, INC. | $1,034.75 | 2023-2025 | |
| Lundbeck LLC | $891.74 | 2021-2025 | Vyepti, Rexulti |
| Genzyme Corporation | $751.96 | 2021-2024 | |
| Upsher-Smith Laboratories LLC | $649.40 | 2021-2023 | |
| Impel Pharmaceuticals INC. | $564.30 | 2022-2023 | Trudhesa |
| Janssen Pharmaceuticals, INC | $532.26 | 2021-2023 | Ponvory |
| Argenx US, INC. | $508.34 | 2023-2025 | Vyvgart Hytrulo |
| Eisai INC. | $492.17 | 2021-2025 | |
| Lilly USA, LLC | $489.85 | 2021-2025 | Amyvid, Kisunla, Emgality |
| Otsuka America Pharmaceutical, INC. | $487.18 | 2023-2025 | Rexulti, Nuedexta |
| Supernus Pharmaceuticals, INC. | $472.05 | 2021-2023 | |
| Celgene Corporation | $457.94 | 2022-2025 | Zeposia |
| Genentech USA, INC. | $449.25 | 2021-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Csl Behring | $421.76 | 2021-2025 | Hizentra, Privigen |
| Sumitomo Pharma America, INC. | $377.76 | 2023-2024 | Aptiom |
| Sunovion Pharmaceuticals INC. | $330.27 | 2021-2022 | |
| Neurelis, INC. | $327.98 | 2021-2025 | Valtoco |
| Avanir Pharmaceuticals, INC. | $294.65 | 2021-2022 | |
| Cycle Pharmaceuticals INC | $277.50 | 2024-2025 | Tascenso Odt, Bafiertam |
| Catalyst Pharmaceuticals, INC. | $265.92 | 2023-2025 | Firdapse |
| Amneal Pharmaceuticals LLC | $249.84 | 2022-2025 | Crexont, Rytary, Lyvispah |
| Astrazeneca Pharmaceuticals LP | $221.20 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $202.28 | 2023-2025 | Ztlido |
| Azurity Pharmaceuticals, INC. | $176.94 | 2023-2025 | Horizant, Horizant |
| Banner Life Sciences, LLC | $169.44 | 2021-2024 | |
| Harmony Biosciences LLC | $151.75 | 2022-2024 | Wakix |
| Kyowa Kirin, INC. | $139.65 | 2022-2024 | Nourianz |
| E.R. Squibb & Sons, L.L.C. | $121.87 | 2021-2023 | Zeposia |
| Tanabe Pharma America, INC. | $119.70 | 2021-2024 | |
| Boston Scientific Corporation | $112.25 | 2022-2023 | |
| Adamas Pharmaceuticals, INC. | $108.09 | 2021 | |
| Mallinckrodt Hospital Products INC. | $91.86 | 2022-2025 | Acthar |
| Alnylam Pharmaceuticals INC. | $90.47 | 2024-2025 | Onpattro |
| Grifols USA, LLC | $86.64 | 2021-2025 | Gamunex-C |
| Avion Pharmaceuticals | $85.67 | 2022-2023 | Dhivy |
| Vanda Pharmaceuticals INC. | $78.89 | 2024-2025 | Ponvory |
| Acorda Therapeutics, INC | $67.31 | 2022-2024 | Inbrija |
| Akcea Therapeutics, INC. | $66.03 | 2021 | |
| Octapharma USA, INC. | $51.65 | 2022-2024 | Cutaquig, Panzyga |
| Xeris Pharmaceuticals, INC. | $39.43 | 2023 | Keveyis |
| Almatica Pharma LLC | $28.93 | 2021 | |
| Amylyx Pharmaceuticals, INC. | $25.70 | 2023 | Relyvrio |
| Impel Pharmaceuticals LLC | $24.03 | 2025 | Trudhesa |
| Averitas Pharma INC. | $23.66 | 2025 | Qutenza |
| Livanova USA, INC. | $22.87 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Merck Sharp & Dohme LLC | $14.49 | 2021 | |
| Currax Pharmaceuticals LLC | $13.57 | 2021 | |
| Collegium Pharmaceutical, INC. | $12.95 | 2022 | |
| Alfasigma USA, INC. | $12.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Swoner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.